Home > Boards > US OTC > Biotechs >

Sunshine Biopharma Inc. (SBFM)

Add SBFM Price Alert      Hide Sticky   Hide Intro
Moderator: Townie, D€N, BooDog, Nadendla, BERKSHIRE AGENT , The Apostle
Search This Board:
Last Post: 2/13/2016 11:46:29 PM - Followers: 344 - Board type: Free - Posts Today: 0




"The Future Of Medicine"


Topoisomerase II is an enzyme that aggressive cancer cells make too much of. When the cell is able to make a lot of the Topoisomerase II 
enzyme, it becomes able to proliferate and metastasize; so, if you can inhibit or destroy the activity of Topoisomerase II, you would then be 
able to prevent cancer cells from spreading. 


Our  Proprietary Technology

Our licensor, Advanomics Corporation, has developed a way to replace the diester bond with a Carbon-Difluoride bond which acts as a perfect diester isostere.  This technology allows us to create a large variety of therapeutic compounds that are completely stable and often more active than the original drugs.  This unique capability allowed us to create our Lead Compound, Adva-27a, an effective and highly specific Topoisomerase II (Top2) Inhibitor. 

Our Carbon-Difluoride Technology is covered by issued and pending patents filed under PCT/FR2003/002330 and PCT/FR2007/000697


Adva-27a is 16-times more effective at killing multidrug resistant  breast cancer cells than Etoposide, the drug currently in use.

Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.

Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies.

Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.

Adva-27a is an excellent inhibitor of Topoisomerase ll with an IC50 of only 13.7 micromolar.

Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats

Adva-27a's initial indication will be multidrug resistant breast cancer for which there are little or no treatment options





Our Published Data show that Adva-27a is a true Topoisomerase ll Inhibitor and is significantly more effevtive at killing aggressive cancer cells than Etoposide, the current drug of choice.

Check out SBFM's drug Adva-27a (27a) vs the leading chem drug Etoposide (2) - results are better in every category except two. And in the multi drug resistance breast cancer category (MCF7R) it's over 3x more effective. 

Unique Features of Adva-27a  

* Adva-27a can be taken orally.
* Adva-27a is not a so-called me-too drug; our technology is unique. Adva-27a will be the only Topoisomerase ll Inhibitor on the Market.
* Adva-27a's initial indication will be multi-drug resistant breast cancer. Adva-27a can be used to treat other Top2 Positive Cancer Types (Prostate, Colon, Lung, Stomach, Ovarian).

The U.S. Food and Drug Administration's (FDA) approval process is likely to be granted fast-track designation since Adva-27a has the potential to help terminally ill patients with no other therapy options and can be used to treat multiple cancer types. As a result of its unique capabilities, versatility and lack of competition, Sunshine Biopharma's Lead Compound could significantly exceed the typical Revenues generated from anti-cancer drugs, which in general reach $1 Billion in annual sales within two or three years of FDA Approval.

Sunshine Biopharma Drug Pipeline

Adva-27a - Completed Preclinicals
Compound for Small-Cell Lung Cancer - In Preclinical Studies
A Third RNAi-Based Drug

November 19, 2014
Montreal, Quebec, Canada -- (Marketwire) -- Sunshine Biopharma Inc. (OTCQB: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today an agreement with Lonza, a leading development and manufacturing company, for the manufacture of its anti-cancer drug, Adva-27a.  Lonza’s expertise and experience in small molecule development and manufacturing of active pharmaceutical ingredients, was an ideal fit for Sunshine’s Adva-27a.  Lonza’s manufacturing capacity ranges from gram quantities for process validation to kilogram amounts for clinical trials and ton quantities for commercialization.  Manufacturing will begin at Lonza’s Nansha, China facility with the remaining key steps to be conducted in Lonza’s high containment cytotoxic facility in Visp, Switzerland.
“We are delighted to have a global leader like Lonza as our manufacturing partner,” said Dr. Steve N. Slilaty, President and CEO of Sunshine Biopharma.  “We have made significant recent strides in terms of research results showing the effectiveness of our lead compound against cancer cells as well as in our manufacturing and recent fund raising efforts.”
“We are very excited to be working with Sunshine Biopharma on the development of their promising anti-cancer compound”, said James Leresche, Ph.D., Head of Lonza’s Chemical Development Services. “This development project is an example of Lonza’s support and commitment to emerging companies with innovative and potentially life-saving treatments like Adva-27a.”
About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 10,000 employees worldwide. The company generated sales of about CHF 3.6 billion in 2013 and is organized into two market-focused segments: Pharma & Biotech and Specialty Ingredients. Further information can be found at
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a Topoisomerase II inhibitor, small molecule that has recently been shown to be effective at killing Multidrug Resistant Breast Cancer cells, Small-Cell Lung Cancer cells, Uterine Sarcoma cells and Pancreatic Cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012).  Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.  The Company is planning a Phase I clinical trial of Adva-27a for Pancreatic Cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant Breast Cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information:
Sunshine Biopharma Media Contacts:
Renmark Financial Communications Inc.
Robert Thaemlitz:
Joshua Ciarrocca:
Tel.: (416) 644-2020 or (514) 939-3989
Sunshine Biopharma Inc. Contacts:
Camille Sebaaly, CFO, Tel.: 514-814-0464,
Lonza Media Contacts:
Colleen Floreck, +1 201 316 9290,
Constance Ward, +41 61 316 8840,
Manufacturing will begin at Lonza’s Nansha, China facility with the remaining key steps to be conducted in Lonza’s high containment cytotoxic facility in Visp, Switzerland.

Nansha China

Visp Switzerland

SBFM SEC Filings

Avastin Ousted By FDA For Breast Cancer, Sunshine Biopharma Gears-Up For Clinicals

We were incorporated in the State of Colorado on August 31, 2006 under the name “Mountain West Business Solutions, Inc.”  During our fiscal year ended July 31, 2009 our business was to provide management consulting with regard to accounting, computer and general business issues for small and home-office based companies.  Effective October 15, 2009, we executed an agreement to acquire Sunshine Biopharma, Inc., a Colorado corporation (“SBI”), in exchange for the issuance of 21,962,000 shares of our Common Stock and 850,000 shares of Convertible Preferred Stock, each convertible into twenty (20) shares of our Common Stock (the “Agreement”).  As a result of this transaction our officers and directors resigned their positions with us and were replaced by our current management.  Following completion of this transaction we changed our name to “Sunshine Biopharma, Inc.”.  On December 21, 2011, Advanomics Corporation, a privately held Canadian company (“Advanomics”), and our licensor, exercised its right to convert the 850,000 shares of Series “A” Preferred Stock it held in our Company into 17,000,000 shares of Common Stock.

Intellectual Property

We are the exclusive licensee for the U.S. territory of Advanomics Corporation’s Adva-27a which is covered by international patent applications filed on April 27, 2007 (PCT/FR2007/000697).  These patent applications, which are now issued in Europe and the United States (US 8,236,935) and are still pending elsewhere around the world, were originally owned by Institut National des Sciences Appliquées de Rouen (France) and have recently been purchased by Advanomics Corporation.  On January 14, 2013, Advanomics Corporation filed a new patent application covering Adva-27a manufacturing processes as well as new Adva-27a derivatives and compositions.
Advanomics Corporation, the Parent Company of Sunshine Biopharma

Head Office:

Advanomics Corporation

2015 Peel Street
5th Floor
Montreal, Quebec H3A 1T8

Tel: 514-764-9698
Fax: 514-764-9699

Sunshine Biopharma Media Contacts:
Renmark Financial Communications Inc.
Robert Thaemlitz:
Joshua Ciarrocca:
Tel.: (416) 644-2020 or (514) 939-3989
Sunshine Biopharma Inc. Contacts:
Camille Sebaaly, CFO, Tel.: 514-814-0464,

Product Pipeline

Our product pipeline is comprised of the following anti-tumor compounds:


Entering Phase I later this year (Lead Compound)



RNAi Anti-Cancer drug candidate
Soon to enter animal studies phase



Currently in preclinical phase


SBFM Share Structure

From and SEC filings
The number of shares of the registrant’s only class of common stock issued and outstanding as of November 10, 2014, was 68,911,041 shares.
The number of shares of the registrant’s only class of Common Stock issued and outstanding as of November 4, 2015, was 137,549,992 shares.

Authorized Shares 200,000,000 a/o Dec 31, 2011

Raised to 500,000,000 in June 2015

31.5 million held by Steve Slilaty, CEO

SBFM Transfer Agent
Corporate Stock Transfer
3200 Cherry Creek Dr. South
Suite 430
Denver, CO 80209
(303) 282 - 4800 p
(303) 282 -  5800 f

Sunshine Biopharma Inc.
2015 Peel Street
5th Floor
Montreal, Quebec H3A 1T8
Tel: 514-764-9698
Fax: 514-764-9699






  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
SBFM News: Four Biotech Small Caps with Near Term Catalysts to Keep on Your Radar 01/27/2016 08:00:00 AM
SBFM News: Current Report Filing (8-k) 12/28/2015 02:12:52 PM
SBFM News: Quarterly Report (10-q) 11/04/2015 02:45:13 PM
SBFM News: Current Report Filing (8-k) 10/09/2015 12:55:42 PM
#27634  Sticky Note Here is the article talking $160M value here: VortMax 01/27/16 07:47:30 AM
#27632  Sticky Note Increasing long term debt is a sure way BooDog 01/27/16 06:25:46 AM
#23558  Sticky Note How about $7B+ yearly in Sales? VortMax 12/30/15 11:06:55 PM
#21973  Sticky Note SBFM Daily Chart Townie 12/16/15 09:52:36 AM
#11692  Sticky Note Please stay on topic. The only topic to IH Admin [Dan] 10/09/13 10:52:01 AM
#28730   Feb 11, 2016 , SBFM article : mandrake1 02/13/16 11:46:29 PM
#28729   Check this : mandrake1 02/13/16 11:44:59 PM
#28728   Soon the 50ma will cross over the 200ma...... PrepareForGlory 02/13/16 11:17:07 PM
#28727   That has been my problem in the past. drivan11 02/13/16 11:07:08 PM
#28726   Well this wont go back down much if brando5 02/13/16 10:21:45 PM
#28725   Therein lies my problem. If it goes to reportmyabuse 02/13/16 08:39:58 PM
#28724   I am going with drpennystock on this one drivan11 02/13/16 07:59:34 PM
#28723   I want more sunshine. I need to go Android 2-73 02/13/16 07:51:07 PM
#28722   Thank you for the thoughtful analysis Dr. Much reportmyabuse 02/13/16 07:45:12 PM
#28721   Very glad to be back in this play, JAM 02/13/16 06:52:44 PM
#28720   Very much appreciated, dr. drivan11 02/13/16 05:01:20 PM
#28719   Video Chart Analysis. Dr PennyStock 02/13/16 04:14:18 PM
#28718   I will post it today at night(Germany time Dr PennyStock 02/13/16 09:05:20 AM
#28717   Thank you very much. I do my best Dr PennyStock 02/13/16 09:03:38 AM
#28716   Biei dilution is a little at a time. drivan11 02/13/16 05:56:25 AM
#28715   That was me drivan11 02/13/16 05:54:50 AM
#28714   How can you be so sure on vldi? drivan11 02/13/16 05:54:16 AM
#28713   SBFM has a GREAT potential ..... short term purefreewater 02/13/16 01:52:17 AM
#28712   $SBFM Chart $Pistol Pete$ 02/12/16 11:01:16 PM
#28711   Welcome!! I think this will be parabolic by drivan11 02/12/16 08:25:46 PM
#28710   Good to know now about OTC, thanks. xtyleradx 02/12/16 08:25:24 PM
#28709   Sounds good. Me neither. Although one drivan11 02/12/16 08:24:30 PM
#28708   Will do. I don't plan on selling soon. xtyleradx 02/12/16 08:23:11 PM
#28707   Good luck. And hang tough. We drivan11 02/12/16 08:17:49 PM
#28706   I sold half my Tpiv and a couple drivan11 02/12/16 08:17:33 PM
#28705   Thanks for the recommendation. I'll look into drpennystock. xtyleradx 02/12/16 08:14:55 PM
#28704   Drpennystock is amazing. He has a website drivan11 02/12/16 08:06:32 PM
#28703   Most likely to keep it in a range Android 2-73 02/12/16 08:04:03 PM
#28702   I'm right around the same price point, just xtyleradx 02/12/16 08:03:53 PM
#28701   Me too. That poster penny stock is drivan11 02/12/16 07:56:25 PM
#28700   Actually no, saw it mentioned on another board xtyleradx 02/12/16 07:54:20 PM
#28699   Is it me where you heard about it drivan11 02/12/16 07:50:37 PM
#28698   I have faith in the science as well. xtyleradx 02/12/16 07:47:50 PM
#28697   1.25 million so I guess 1%. Lol. drivan11 02/12/16 07:45:41 PM
#28696   Damn Ivan, plan on being a part-owner? xtyleradx 02/12/16 07:40:43 PM
#28695   Added 250000. You have time. This drivan11 02/12/16 07:36:41 PM
#28694   Looking forward to it,...should of bought more today. Canoepaddler 02/12/16 07:01:26 PM
#28693   Added a bunch today. Certainly hope so drivan11 02/12/16 06:52:47 PM
#28692   You are a good soul Dr. This is TEXASOIL 02/12/16 06:44:39 PM
#28691   Tomorrow I will post here a video with Dr PennyStock 02/12/16 04:26:59 PM
#28690   Yes, good close, 18% above the MA200. Better Dr PennyStock 02/12/16 04:22:26 PM
#28689   Nice close Doc. Btw, I'll be checking out BooDog 02/12/16 04:14:11 PM
#28688   Not exactly what I wanted today, but, not Dr PennyStock 02/12/16 04:10:41 PM
#28687   SBFM low mc! Less than 2 mill! Breakthrough brando5 02/12/16 03:48:36 PM
#28686   $SBFM is only worth $2M Mc!,Yet they are brando5 02/12/16 03:47:56 PM
#28685   Yes, it causes that effect. CSTI could move Dr PennyStock 02/12/16 03:45:42 PM
#28684   The big blocks on the ask might make dbchamps 02/12/16 03:12:18 PM
#28683   And now CSTI dropped to .016 with 100k Dr PennyStock 02/12/16 03:01:56 PM
#28682   Yes, it is CSTI. I know that several Dr PennyStock 02/12/16 02:48:14 PM
#28681   more than our daily shares traded so far kwags34 02/12/16 02:30:04 PM